# US 11,433,128 B2 · Cell surface anchoring antigen conjugates to treat cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,433,128 B2
- Document ID: US11433128B2
- Status: Granted
- Kind: B2
- Application number: 15/945,741
- Filed: 2018-04-05
- Published: 2018-11-01
- Granted: 2022-09-06
- Earliest claimed: 2017-04-07
- Applicants: Tianxin Wang
- Inventors: Tianxin Wang
- Web page: https://patentgrep.com/patent/US11433128B2

## CPC

- A61K 39/107: {Vibrio}
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/575: substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A61K 39/0011: {Cancer antigens}
- A61P 35/00: Antineoplastic agents
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K 2039/60: {characteristics by the carrier linked to the antigen}
- A61K 2039/6018: {Lipids, e.g. in lipopeptides}
- A61K 2039/627: {characterised by the linker}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure provides cell surface anchoring antigen conjugates, formulations comprising cell surface anchoring antigen conjugates, and methods of using the same for treating cancer.

## Claims

### Claim 1

A pharmaceutical composition comprising a cell surface anchoring antigen conjugate and a Toll-like receptors (TLR) agonist selected from a group consisting of poly IC, imiquimod or a mixture thereof, wherein the cell surface anchoring antigen conjugate contains a 3β-cholesterylamine moiety and a galactose-alpha-1,3-galactose (α-gal) moiety as antigen of pre-existing endogenous anti α-gal antibody, having a formula:
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the Toll-like receptors agonist is encapsulated in a particle.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein the cell surface anchoring antigen conjugate further comprises more than one copies of α-gal.

### Claim 4

A pharmaceutical composition comprising a cell surface anchoring antigen conjugate and a Toll-like receptors (TLR) agonist selected from a group consisting of poly IC, imiquimod or a mixture thereof, wherein the cell surface anchoring antigen conjugate is a conjugate of L-rhamnose with 3β-cholesterylamine having formula:
or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 4)

The pharmaceutical composition of claim 4, wherein the Toll-like receptors agonist is encapsulated in a particle.

### Claim 6 (depends on 4)

The pharmaceutical composition of claim 4, wherein the cell surface anchoring antigen conjugate further comprises more than one copies of L-rhamnose.